Effect of secukinumab on bone formation markers in patients with active ankylosing spondylitis
Corresponding Author
Grigorios T. Sakellariou
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Correspondence
Grigorios T. Sakellariou, Department of Rheumatology, 424 General Army Hospital, Ring Road N.Efkarpias, Thessaloniki 564 03, Greece.
Email: [email protected]
Search for more papers by this authorMaria Konsta
Department of Rheumatology, Sismanoglio Hospital, Athens, Greece
Search for more papers by this authorIoanna Katsigianni
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this authorDimitrios Deligeorgakis
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this authorDimitrios Zisopoulos
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this authorPeriklis Vounotrypidis
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this authorCorresponding Author
Grigorios T. Sakellariou
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Correspondence
Grigorios T. Sakellariou, Department of Rheumatology, 424 General Army Hospital, Ring Road N.Efkarpias, Thessaloniki 564 03, Greece.
Email: [email protected]
Search for more papers by this authorMaria Konsta
Department of Rheumatology, Sismanoglio Hospital, Athens, Greece
Search for more papers by this authorIoanna Katsigianni
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this authorDimitrios Deligeorgakis
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this authorDimitrios Zisopoulos
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this authorPeriklis Vounotrypidis
Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece
Search for more papers by this author
CONFLICT OF INTEREST STATEMENT
The authors declare that they have no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
All data used for this study are published in this manuscript. Further information is available upon reasonable request to the corresponding author.
REFERENCES
- 1Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009; 60: 3257-3262.
- 2Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012; 71: 572-574.
- 3Sakellariou GT, Anastasilakis AD, Bisbinas I, et al. Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. Rheumatology (Oxford). 2015; 54: 908-914.
- 4Solmaz D, Uslu S, Kozaci D, et al. Evaluation of periostin and factors associated with new bone formation in ankylosing spondylitis: periostin may be associated with the Wnt pathway. Int J Rheum Dis. 2018; 21: 502-509.
- 5Gravalesse EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018; 14: 631-640.
- 6Daoussis D, Kanellou A, Panagiotopoulos E, Papachristou D. DKK-1 is underexpressed in mesenchymal stem cells from patients with ankylosing spondylitis and further downregulated by IL-17. Int J Mol Sci. 2022; 23: 6660.
- 7Braun J, Baraliakos X, Deodhar A, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the measure 1 study. Rheumatology (Oxford). 2019; 58: 859-868.
- 8Braun J, Buehring B, Baraliakos X, et al. Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1. BMC Musculoskelet Disord. 2021; 22: 1037.
- 9Fassio A, Gatti D, Rossini M, et al. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clin Exp Rheumatol. 2019; 37: 133-136.
- 10Descamps E, Anna Molto A, Didier Borderie D, et al. Changes in bone formation regulator biomarkers in early axial spondyloarthritis. Rheumatology (Oxford). 2021; 60: 1185-1194.
- 11Rossini M, Viapiana O, Luca Idolazzi L, et al. Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with ankylosing spondylitis. Calcif Tissue Int. 2016; 98: 438-445.
- 12Nocturne G, Pavy S, Boudaoud S, et al. Increase in Dickkopf-1 serum level in recent spondyloarthritis. Data from the DESIR cohort. PloS One. 2015; 10:e0134974.
- 13Saad CG, Ribeiro AC, Moraes JC, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti- tumor necrosis factor therapy? Arthritis Res Ther. 2012; 14: R216.
- 14Rademacher J, Siderius M, Gellert L, et al. Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy. Semin Arthritis Rheum. 2022; 53:151974.
- 15Korkosz M, Gąsowski J, Leszczyński P, et al. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. Scand J Rheumatol. 2014; 43: 43-48.
